PIM2

Serine/threonine-protein kinase pim-2

120,750 patent compounds predicted against PIM2, 66,051 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL319071	0.64	20/20
SCHEMBL327448	0.63	20/20
SCHEMBL319029	0.63	20/20
SCHEMBL319072	0.60	20/20
SCHEMBL319025	0.58	20/20
SCHEMBL319198	0.58	20/20
SCHEMBL319325	0.57	20/20
SCHEMBL319581	0.56	20/20
SCHEMBL319019	0.56	20/20
SCHEMBL319494	0.55	20/20
SCHEMBL319678	0.55	20/20
SCHEMBL318980	0.54	20/20
SCHEMBL319635	0.54	20/20
SCHEMBL319834	0.54	20/20
SCHEMBL319256	0.53	20/20
SCHEMBL319399	0.53	20/20
SCHEMBL319793	0.53	20/20
SCHEMBL320006	0.53	20/20
SCHEMBL325024	0.52	20/20
SCHEMBL325025	0.52	20/20

Germline variants in PIM2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PIM2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PIM2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	PHASE3	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML	PHASE2	RECRUITING
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer	PHASE2	RECRUITING
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma	PHASE2	ACTIVE_NOT_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma	PHASE2	RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer	PHASE2	ENROLLING_BY_INVITATION
A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects	PHASE1	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects	PHASE1	COMPLETED
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function	PHASE1	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Evaluation of Hypoxia in Primary Melanoma	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PIM2 binder may also engage these)

Protein	Name	Similarity
B1WBU5	—	0.977	B1WBU5 →
P0C5K1	—	0.976	P0C5K1 →
Q95LJ0	—	0.972	Q95LJ0 →
PKN3	Serine/threonine-protein kinase N3	0.969	landscape →
SBK3	Uncharacterized serine/threonine-protein kinase SBK3	0.969	landscape →
Q9N0P9	—	0.968	Q9N0P9 →
Q8K045	—	0.965	Q8K045 →
P0C263	—	0.965	P0C263 →
P58750	—	0.965	P58750 →
PIM1	Serine/threonine-protein kinase pim-1	0.964	landscape →
O70444	—	0.964	O70444 →
P26794	—	0.963	P26794 →
P06803	—	0.962	P06803 →
P0C5K0	—	0.960	P0C5K0 →
Q4FZD7	—	0.960	Q4FZD7 →
Q62070	—	0.959	Q62070 →
P08923	—	0.958	P08923 →
PIM3	Serine/threonine-protein kinase pim-3	0.958	landscape →
PLK3	Serine/threonine-protein kinase PLK3	0.956	landscape →
Q9R011	—	0.954	Q9R011 →
Q60806	—	0.954	Q60806 →
P23049	—	0.953	P23049 →
A8VU90	—	0.953	A8VU90 →
Q28616	—	0.953	Q28616 →
Q49HH9	—	0.952	Q49HH9 →
Q99ML2	—	0.952	Q99ML2 →
Q643R3	—	0.952	Q643R3 →
AXL	Tyrosine-protein kinase receptor UFO	0.951	landscape →
Q91ZT7	—	0.951	Q91ZT7 →
LTK	Leukocyte tyrosine kinase receptor	0.951	landscape →